BidaskClub cut shares of Uniqure (NASDAQ:QURE) from a buy rating to a hold rating in a research note published on Wednesday.
QURE has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Uniqure from a hold rating to a sell rating in a report on Wednesday, January 10th. ValuEngine upgraded shares of Uniqure from a sell rating to a hold rating in a report on Friday, February 2nd. HC Wainwright set a $35.00 price target on shares of Uniqure and gave the company a buy rating in a report on Tuesday, February 20th. Finally, Janney Montgomery Scott assumed coverage on shares of Uniqure in a report on Wednesday, January 3rd. They issued a buy rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $21.38.
Shares of Uniqure stock opened at $21.96 on Wednesday. The firm has a market cap of $714.79, a price-to-earnings ratio of -7.47 and a beta of 0.18. The company has a quick ratio of 8.46, a current ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure has a one year low of $4.72 and a one year high of $27.19.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.23). The firm had revenue of $2.58 million for the quarter, compared to analysts’ expectations of $2.83 million. Uniqure had a negative return on equity of 174.25% and a negative net margin of 604.72%. equities research analysts forecast that Uniqure will post -3.21 earnings per share for the current year.
In related news, insider Deventer Sander Van sold 5,985 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $18.53, for a total value of $110,902.05. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 39,169 shares of the stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $21.72, for a total transaction of $850,750.68. Following the completion of the sale, the chief executive officer now directly owns 439,764 shares in the company, valued at $9,551,674.08. The disclosure for this sale can be found here. Insiders sold a total of 48,032 shares of company stock valued at $1,014,982 in the last quarter. Insiders own 0.73% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in Uniqure in the 4th quarter valued at about $119,000. Perceptive Advisors LLC grew its stake in Uniqure by 0.8% in the 4th quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock valued at $20,529,000 after acquiring an additional 7,831 shares during the last quarter. Ellington Management Group LLC acquired a new stake in Uniqure in the 4th quarter valued at about $237,000. Goldman Sachs Group Inc. acquired a new stake in Uniqure in the 4th quarter valued at about $373,000. Finally, Virtus Fund Advisers LLC acquired a new stake in Uniqure in the 4th quarter valued at about $389,000. 42.76% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/uniqure-qure-downgraded-to-hold-at-bidaskclub.html.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.